Welcome to our dedicated page for Adapthealth SEC filings (Ticker: AHCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AdaptHealth Corp. filings document the company’s healthcare-at-home operations, financial reporting and public-company governance. Its Form 8-K disclosures include quarterly and annual earnings releases, Regulation FD updates, financial guidance, business highlights and material events related to operating partnerships, asset dispositions and executive leadership changes.
The filing record also covers capital structure and financing matters, including credit agreements entered into by AdaptHealth LLC and related guarantees, collateral and borrowing commitments. AdaptHealth’s proxy materials describe board and executive compensation matters, while its securities disclosures identify common stock trading under AHCO on the Nasdaq Stock Market.
AdaptHealth Corp. insider Richard W. Rew II, the company’s CLO and General Counsel, reported an open-market purchase of 5,000 shares of common stock at $8.91 per share. Following this Form 4 transaction, his directly owned AdaptHealth shareholdings increased to 107,097 shares.
AdaptHealth Corp. filed its annual report describing a large U.S. home-care platform focused on sleep, respiratory, diabetes and broader wellness-at-home products and services. The company operates four segments and, as of December 31, 2025, served about 4.3 million patients through roughly 640 locations in 48 states.
Revenue is diversified across resupply and one-time sales (about 63% of 2025 net revenue), monthly rental equipment (about 33%) and at-risk capitation contracts (about 4%). The report highlights reliance on a few key suppliers, heavy exposure to Medicare, Medicaid and private payors, significant regulatory and reimbursement uncertainty, cybersecurity and AI-related risks, inflation and labor pressures, and potential impacts from new U.S. health and climate-related laws.
AdaptHealth Corp. reported essentially flat 2025 sales but a swing to loss and outlined higher 2026 targets. Net revenue for 2025 was $3,244.9 million, down 0.5%, while net loss attributable to AdaptHealth was $70.8 million versus prior-year net income of $90.4 million, driven in part by a $128.0 million non-cash goodwill impairment in the Diabetes Health unit. Adjusted EBITDA fell 10.5% to $616.7 million, and fourth quarter Adjusted EBITDA declined 18.7% to $163.1 million, including a $14.5 million legal settlement expense and over $10 million of strategic investments. Cash flow from operations remained strong at $601.8 million, up from $541.8 million, with full-year free cash flow of $219.4 million. The company reduced debt by $250 million in 2025 and received credit upgrades from S&P and Moody’s. For 2026, AdaptHealth guides to net revenue of $3.44–$3.51 billion, Adjusted EBITDA of $680–$730 million, and free cash flow of $175–$225 million, reflecting expectations for improved profitability after a transition year.
FMR LLC and Abigail P. Johnson report beneficial ownership of 7,631,435.08 shares of AdaptHealth Corp common stock, representing 5.6% of the class as of 12/31/2025. FMR has sole voting power over 7,626,717 shares and sole dispositive power over 7,631,435.08 shares.
The filing states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of AdaptHealth. One or more other persons may receive dividends or sale proceeds, but no such person holds more than five percent of the outstanding common stock.
AdaptHealth Corp.'s Chief Legal Officer and General Counsel, Richard W. Rew II, reported an equity award of 53,688 shares of common stock on January 30, 2026, coded as an acquisition. The filing shows these shares as restricted stock units that will be settled in common stock when they vest.
After this grant, Rew beneficially owned a total of 102,097 shares of AdaptHealth common stock in direct ownership, reflecting his updated equity stake as a senior officer.
AdaptHealth Corp.’s Chief Commercial Officer Russell E. Schuster III reported an equity award of 48,807 shares of common stock on 01/30/2026. The Form 4 shows the transaction coded as an acquisition at a reported price of $0.00 per share, indicating a stock-based grant.
A footnote explains these 48,807 shares are restricted stock units that will be settled in common stock upon vesting. After this award, Schuster beneficially owns 147,813 shares of AdaptHealth common stock in direct form.
AdaptHealth Corp.'s Chief Operating Officer, Toby Scott Barnhart, received a grant of restricted stock units (RSUs). On 01/30/2026, he was awarded 68,330 shares of common stock at a price of $0 per share, classified as an acquisition.
These RSUs will be settled in AdaptHealth common stock upon vesting, meaning the shares are delivered over time as conditions are met. Following this grant, Barnhart beneficially owns 220,654 shares of AdaptHealth common stock in direct ownership.
AdaptHealth Corp.'s Chief Technology Officer, Albert A. Prast, reported an equity award in the form of restricted stock units. On January 30, 2026, he acquired 63,449 shares of common stock at $0 per share, representing restricted stock units that will settle in common stock upon vesting. Following this grant, he beneficially owned 442,907 shares of AdaptHealth common stock in direct ownership.
AdaptHealth Corp. reported that Chief Business Systems Officer Daniel McFadden received an award of 29,284 shares of common stock on 01/30/2026. The shares are in the form of restricted stock units that will convert into common stock when they vest.
Following this grant, McFadden beneficially owns 83,242 shares of AdaptHealth common stock in direct ownership. The award was reported at a price of $0 per share, consistent with a typical equity compensation grant rather than an open-market purchase.
AdaptHealth Corp. Chief Executive Officer and director Suzanne Foster reported an award of 329,449 shares of common stock on January 30, 2026. The filing explains these shares are restricted stock units that will be settled in common stock when they vest, effectively tying compensation to future service or performance.
After this grant, Foster directly beneficially owns 924,050 shares of AdaptHealth common stock. The transaction price is shown as $0 per share, consistent with a stock-based compensation grant rather than an open-market purchase.